| A Prospective, Exploratory Study of Becotatug Vedotin Plus Putlimab for Neoadjuvant Therapy and Adjuvant Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma (NCT07707167) | Jiangsu Cancer Institute & Hospital | 2026-08-31 |
| A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal Cance (NCT07622550) | Jiangsu Cancer Institute & Hospital | 2026-06-15 |
| A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer (NCT07446387) | Jiangsu Cancer Institute & Hospital | 2026-05-30 |
| Precision Nursing vs Conventional Care in Laparoscopic Colorectal Cancer Surgery: A Randomized Controlled Trial (NCT07413510) | Jiangsu Cancer Institute & Hospital | 2026-05-01 |
| QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer (NCT07601178) | Jiangsu Cancer Institute & Hospital | 2026-04-17 |
| Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (NCT07408609) | Jiangsu Cancer Institute & Hospital | 2026-02-26 |
| Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer (NCT07407452) | Jiangsu Cancer Institute & Hospital | 2026-02-01 |
| Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study (NCT07311577) | Jiangsu Cancer Institute & Hospital | 2026-01-01 |
| Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal Carcinoma (NCT05912582) | Jiangsu Cancer Institute & Hospital | 2025-12-25 |
| Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial (NCT07286942) | Jiangsu Cancer Institute & Hospital | 2025-12-18 |
| Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (NCT07435454) | Jiangsu Cancer Institute & Hospital | 2025-12-01 |
| A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer (NCT07082179) | Jiangsu Cancer Institute & Hospital | 2025-09-04 |
| A Study on Immunotherapy Combined With Radiotherapy for Esophagogastric Junction/Gastric Adenocarcinoma (NCT07053332) | Jiangsu Cancer Institute & Hospital | 2025-07-01 |
| Benmelstobart-Anlotinib-Chemo for Neoadjuvant Oral Cancer (NCT06848439) | Jiangsu Cancer Institute & Hospital | 2025-06-15 |
| Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC. (NCT07009925) | Jiangsu Cancer Institute & Hospital | 2025-06-01 |
| Adebrelimab With Chemoradiotherapy and Surgery for G/GEJ (NCT06985602) | Jiangsu Cancer Institute & Hospital | 2025-05-16 |
| Sintilimab in Combination with Chemotherapy ± Local Treatment for Om-G/GEJ (NCT06739161) | Jiangsu Cancer Institute & Hospital | 2024-12-02 |
| MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC (NCT06198868) | Jiangsu Cancer Institute & Hospital | 2024-02-01 |
| High- and Low-dose Radiotherapy Combined With PD-1 Inhibitors for MSS CRLM (NCT06045286) | Jiangsu Cancer Institute & Hospital | 2023-09-20 |
| Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJ (NCT05941481) | Jiangsu Cancer Institute & Hospital | 2023-06-10 |
| Retrospective Study on the Prediction of Radiation-induced Brain Injury in Patients With Nasopharyngeal Carcinoma (NCT06244394) | Jiangsu Cancer Institute & Hospital | 2023-06-01 |
| Study of Polymeric Micellar Paclitaxel, Platinum Combined With Sindilizumab Injection for Advanced Non-squamous NSCLC (NCT05782426) | Jiangsu Cancer Institute & Hospital | 2023-03-15 |
| Low-Dose Radiation Therapy for Severe COVID-19 Pneumonia (NCT05694962) | Jiangsu Cancer Institute & Hospital | 2023-01-01 |
| Chemo-immunotherapy Induction Followed by Hypo-radiotherapy in LA-NSCLC(CHIC) (NCT05784142) | Jiangsu Cancer Institute & Hospital | 2022-10-27 |
| RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2 (NCT05417230) | Jiangsu Cancer Institute & Hospital | 2022-08-01 |
| Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC (NCT05394415) | Jiangsu Cancer Institute & Hospital | 2022-05-01 |
| Short Course Neoadjuvant Chemo-radiotherapy Plus Toripalimab for Locally Advanced Resectble Squamous Cell Carcinoma of Esophagus (NCT05424432) | Jiangsu Cancer Institute & Hospital | 2022-04-29 |
| A Study of SVZ Irradiation With Postoperative Radiotherapy in Patients With GBM. (NCT06092255) | Jiangsu Cancer Institute & Hospital | 2022-03-01 |
| Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer (NCT04929652) | Jiangsu Cancer Institute & Hospital | 2021-06-01 |
| Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase Ⅲ Clinical Study (NCT07306663) | Jiangsu Cancer Institute & Hospital | 2021-06-01 |
| A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab Vedotin (NCT04624893) | Jiangsu Cancer Institute & Hospital | 2019-12-12 |
| A Study of Cetuximab Plus Raltitrexed for Maintenance Treatment in Advanced Colorectal Cancer (NCT04241731) | Jiangsu Cancer Institute & Hospital | 2019-11-28 |
| A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer (NCT04324476) | Jiangsu Cancer Institute & Hospital | 2019-09-01 |
| Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma (NCT03932266) | Jiangsu Cancer Institute & Hospital | 2019-06-01 |
| An Observational Study to Explore Clinical Characteristics of the Patients With T1 Non-small Cell Lung Cancer (NCT03413956) | Jiangsu Cancer Institute & Hospital | 2017-12-01 |
| Study of the Combination of TACE With Apatinib in Patients With Hepatocellular Carcinoma (NCT03066557) | Jiangsu Cancer Institute & Hospital | 2017-03-15 |
| Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer (NCT03126071) | Jiangsu Cancer Institute & Hospital | 2017-02-15 |
| Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer (NCT02485548) | Jiangsu Cancer Institute & Hospital | 2015-06-01 |
| NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation (NCT01694576) | Jiangsu Cancer Institute & Hospital | 2012-09-01 |
| Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC) (NCT01712919) | Jiangsu Cancer Institute & Hospital | 2010-05-01 |